Background: Atopic dermatitis (AD) is a common allergic skin disease in which genetic and 39 environmental factors influence the development of skin barrier and immune system 40 dysfunction. Recently, evidence has emerged to support the notion that skin microbial flora can 41 modulate development and exacerbation of this disease. Our study is the first to characterise the 42 skin microbiome in Thai patients with atopic dermatitis before and after 4-week monotherapy 43 with tarcolimus. 44 Methods: Swab samples from skin lesions at volar forearm of 9 patients with atopic dermatitis 45 and normal skin samples of 12 healthy subjects were collected. The skin microbiome was 46 characterized using 16S ribosomal RNA gene sequencing. 47 Results: The diversity of skin microbes is significantly different between the control and AD 48 subjects. Lower prevalence of Actinobacteria and Gammaproteobacteria, but higher prevalence 49 of Firmicutes was observed in the AD group. A significant increase in Staphylococcus spp. but 50 decrease in several commensals such as Coryebacterium spp. and Dermacoccus spp. Was 51 detected in AD compared to healthy subjects. After treatment with tacrolimus, the skin 52 microbiota composition of AD individuals was comparable to the control group.
Introduction

58
Atopic dermatitis (AD) is a common inflammatory skin disease, the prevalence of which 59 varies from 5-30% worldwide., and it is clear that incidence of AD has increased recently in 60 industrial countries 1,2 . The disease is chronic and often heralds other atopic diseases such as 61 asthma and allergic rhinitis. 3 Therefore, AD has become one of the most burdensome skin 62 diseases amongst people of all ages and ethnic backgrounds. The disease is characterised by a 63 dysfunctional skin barrier and associated immune response leading to chronic eczematous skin 64 eruptions. Both genetic and environmental inputs play roles in the development and 65 maintenance of the disease. In particular, several factors have been found to promote AD 66 including exposure to irritant substances, and recently the advance in metagenomics coupled 67 next generation sequencing has specifically identified dysbiosis of skin microbiome as being a 68 major factor. Excessive hyginene associated with urban lifestyle may lead to altered microbial 69 skin contact especially in early life, which results in dysbiosis and immune dysregulation in 70 AD. 71 Recent research has revealed the role of dysbiosis of the skin microbiome in 72 pathogenesis of AD. A reduction in antimicrobial peptides, defects of epidermal barrier and 73 dysregulation of the adaptive immune response results in a corresponding increase in skin 74 colonization by Staphylococcus aureus, which leads to a loss of skin bacterial diversity and 75 increases in specific IgE antibodies against bacterial toxins in the patients' serum. 4 Meta- 76 analysis reports estimated that pool prevalence of S. aureus colonization in AD skin lesion was 77 70 % and the prevalence of colonization correlated with disease severity. 5 Furthermore, S. 78 aureus has been reported to facilitate skin inflammation and barrier dysfunction via several 79 mechanisms. [6] [7] [8] [9] Beside the conolization of S. aureus in AD skin lesions dysbiosis of the skin 80 microbiome via reduction of commensal microbes such as Staphylococcus epidermidis, 81 Propionibacterium spp. and Corynebacterium spp. has been evident in AD. In normal life, S. Several therapeutic approaches exist for AD and these can act by specifically by 87 restoring the skin barrier, diminishing skin imflammation and reversing dysbiosis of skin 88 microbiome. Topical corticosteroids have been used alone or in combination with topical 89 antibiotics due to their cost-effectiveness. Nowadays, topical caucineurin inhibitors (TCIs) 90 have been recommened as a maintenance therapy as they are low risk of triggering adverse 91 events. To date, there is a paucity of information on the effect of TCIs on skin microbiome in 92 AD and our study seeks to address this. Our aim is to report the findings of a comprehensive 93 comparison of the healthy and AD skin microbiome following the introduction of tacrolimus. 94 We report for the first time that the anti-inflammatory effect of tacrolimus is sufficient to 95 restore the skin barrier leading to reversed dysbiosis of the skin microbiota in a Thai cohort excluded from the study. All patients were free from systemic skin therapies for at least 4 107 weeks, systemic antibiotics for at least 6 months or topical skin therapies and topical antiseptics 108 for at least 2 weeks prior to sample collection. Patients were allowed to use only mild liquid 109 soap and 10% urea cream for 2 weeks and avoid all washing 24 hours prior to sampling. The 110 study was approved by the ethical committee of the King Chulalongkorn University. All 111 participants provided informed consent. The demographic as well as the severity scales of AD 112 (before and after tarcolimus treatment) data are shown in Table 1 . For abbreviation, 'D' denotes 113 disease, 'Bf' or 'Before' and 'Af' or 'After' denote AD-before and AD-after treatment, and the 114 number in the middle denotes individual patient in random order. Similarly, 'C' denotes control 115 followed by the number that denotes individual normal volunteer in random order. . 13 Then, samples were centrifuged at 10,000g for 5 minutes, and supernatant was removed.
121
The sample pellet was kept at -80 °C. Total genomic DNA was extracted from the pellet by 122 GenElute bacterial genomic DNA kit (Sigma). Finally, genomic DNA was kept at -80°C. analysis effect size (LEfSe) to find biomarkers between two or more groups from relative 158 abundances 21 were performed using mother. Table 2 ). The number of GLOTUs 175 vary from 6 to 162; hence, the diversity assessment within each microbiota was assessed 176 (OTUs, Chao and Shannon) and the the variance box plot analysis showed that the species Table 2 ).
181
Taxonomic profiles demonstrated the diversity that might differ among the control and 182 the AD: phylum Actinobacteria (class Actinobacteria) was relatively high in control followed 183 by Proteobacteria (class Gammaproteobacteria), whereas phylum Firmicutes (class Bacilli) was 184 generally higher in the AD, in particular the Bf group (Figures 2A and 2B) . In detail, the Af 185 group showed closer relative abundances of Actinobacteria by increasing from the matched Bf 
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When analysis without the D8 showed even more prominent the community structure 194 difference between the control and the disease groups with the AMOVA statistic of p < 0.001 195 ( Figure 3A and B) . (AMOVA p = 0.003) was suggested greater than between the Control-Af (AMOVA p = 0.15). where D8 data were exempted. Nevertheless, the p-value statistic between the Bf and Af groups 205 remained non-significant (AMOVA p = 0.164).
206
Metastats analysis highlighted species that were differentially statisticaly different 207 between the comparing groups. Consistently, compared to the control group, there were a fewer 208 number of species differences in the Af than the Bf groups (Supplemental Table 3 ).
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Supplemental Table 3A allergy-defensive action of these commensals and allergy-provocation of S. aureus related to 252 AD has been observed. 23, 24 Our data is unique in the fact that it highlights lower prevalence of 253 phylum Actinobacteria (class Actinobacteria) and Proteobacteria (class Gammaproteobacteria), 
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Several therapies for AD aim to reduce the bacterial load leading to attenuated 265 inflammation, restored skin barrier and reversed dysbiosis of skin microbiome. Tacrolimus, a 266 TCI, has been widely used as a effective and safe treatment in AD. To the best of our 267 knowledge, the effect of TCIs on skin microbiome has never before been reported. We 268 discovered that after treatment with tacrolimus, the skin microbiota structure of AD returned to 269 be comparable to control group. Furthermore, the fewer number of species differences in the Af 270 group than the Bf group when compared to control. This finding refected that tacrolimus could 271 reverse some dysbiosis in AD. Nonetheless, there are some remaining species that may still 272 persist to promote AD after treatment with tacrolimus. These species may require additional 273 treatment either to equilrerate those species to the relative abundances representing the control 274 subjects.
275
Tacrolimus can restore the skin barrier by several mechanisms. It acts as an 276 immunosuppressive agent by inhibiting the activation of T cellsn and suppressing scytokines 277 production by them. Additionally, tacrolimus has been report to alleviate pruritis by suppressing 278 13 sensory nerve activation. 26 Therefore, it is possible that the influence of tacrolimus in restitution 279 of the skin microbiome might be a consequence of its anti-inflammatory effect and potential to 280 restore the skin barrier.
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To date, various methods have been used for skin microbiome analysis. Our study 282 analyzed skin microbiome in AD using 16S rRNA gene sequence. It should be note that the 283 power of species and genus classification is in part limited by the partial 16S rRNA gene 284 sequence. For future experiments of this nature, the unclassified and classified isolates of 285 interest might be full-length sequenced to confirm the species annotation.
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In conclusion, this study for the first time characterises the skin microbiota in healthy 287 and patients with AD in Thailand (a tropical country). Several mechanisms of tacrolimus 288 efficacy in treatment of AD have been suggested. This study is the first original research study 289 to describe the effect of tacrolimus on the skin microbiome in AD, and it may further influence 290 the use of tacrolimus as a strategy toi alleviate AD in the future. 
